Leucadia Pharmaceuticals Launches Acetaminophen Injection

Leucadia Pharmaceuticals has launched its acetaminophen injection, 1000 mg/100 mL (10 mg/mL), an FDA-approved generic version of Ofirmev (Mallinckrodt Pharmaceuticals).

Acetaminophen injection is indicated for the management of mild-to-moderate pain, management of moderate-to-severe pain with adjunctive opioid analgesics, and reduction of fever. According to Leucadia, it is AP rated, bar coded, preservative free, and does not contain natural rubber latex.

The launch expands Leucadia’s line of generic injections approved by the FDA, which also includes the first generic to the novel antineoplastic agent valrubicin sterile solution for intravesical instillation, sodium tetradecyl sulfate injection generic, and icatibant injection generic.

“The release of this latest generic injectable once again demonstrates Leucadia’s strategic focus on expanding access to safe, effective pharmaceuticals at substantially lower costs,” Dr William Larkins, chief executive officer of Leucadia Pharmaceuticals, said in a press release. “Acetaminophen injection is a widely proven therapy for the reduction of pain and fever and demand for expand options in this market is extremely robust.”

Reference

1. Leucadia Pharmaceuticals Launches Acetaminophen Injection. Press release. Leucadia; December 7, 2020. Accessed December 21, 2020. https://leucadiapharma.com/wp-content/uploads/2020/12/Leucadia-Pharma_Acetaminophen-Injection-Release.pdf